Development of GDNF Receptor Conditional Knockout Mice
GDNF受体条件性敲除小鼠的研制
基本信息
- 批准号:7420970
- 负责人:
- 金额:$ 17.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-01 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdultAgeAgingAnatomyAnimalsBindingBiological ModelsBirthCellsCessation of lifeClinicalCollaborationsCorpus striatum structureCoupledDataDependenceDevelopmentDevelopmental BiologyDevelopmental ProcessDiseaseDisruptionDopaminergic CellDrug FormulationsEnsureEnvironmentFamilyGDNF geneGDNF receptorsGenerationsGenesGenetic TechniquesGerm LinesGoalsGrowth FactorHumanInterruptionKidneyKnock-in MouseKnock-outKnockout MiceLaboratoriesLeadLearningLifeLigandsLightMaintenanceMarylandMethodsModelingMusMutant Strains MiceMutationNational Institute of Mental HealthNeonatalNeonatal MortalityNeurodegenerative DisordersNeurologyNeuronsNumbersParkinson DiseasePathologicPathologyPerinatalPhenotypePhosphotransferasesPlayPoint MutationProtein KinaseProtein Tyrosine KinaseProteinsQuality of lifeReceptor InhibitionResearchResearch PersonnelRoleSignal TransductionSpecificitySubstantia nigra structureSymptomsSystemThinkingTimeToxinTrainingUniversitiesWeekWorkcell typechemical geneticsdaydisabilitydopaminergic neurongastrointestinalgenetic manipulationglial cell-line derived neurotrophic factorinhibitor/antagonistinterestmalformationmature animalmodel developmentmouse modelnervous system disorderneurturinnigrostriatal systemnovelpersephinpostnatalpreferenceprogramsreceptorrecombinasesuccesstheories
项目摘要
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a common neurologic disorder whose symptoms progress relentlessly toward severe disability and loss of quality of life. One promising potential therapy is glial cell line-derived neurotrophic factor (GDNF). GDNF is a naturally occurring growth factor that has been shown in a variety of model systems to support the survival of those dopaminergic cells that are lost in PD. Attempts to learn more about the functions of GDNF through the generation of mice lacking this factor or its receptors have been thwarted by accompanying renal and gastrointestinal abnormalities leading to early postnatal death. Through the use mice recently developed by the applicant that express Cre recombinase in dopaminergic neurons and by using powerful new chemical/genetic techniques to generate receptor inhibition, the applicant's overall goal is to generate viable mice that have cell-type specific and temporally-specific interruption of GDNF signaling. Such mice will be used as a model system to examine the role of endogenous GDNF in the postnatal development and maintenance of those cells lost in Human PD. Initial work done by the applicant in the laboratory of Dr. Ted Dawson at Johns Hopkins has generated preliminary data toward accomplishing this goal. His interest in developmental biology and neurodegenerative disease led to the formulation of this project and is derived from previous research at the NIMH, University of Maryland and Johns Hopkins University and from clinical training in neurology. The expertise in models of Parkinson's disease found in the Dawson laboratory (Sponsor) and collaborations set up with leaders in the field of growth factors (Dr. Ginty) and specific kinase inhibition (Dr. Shokat) make the potential for success in this project high. This coupled with the rich environment present in the sponsor's laboratory and in the Johns Hopkins Neurology Department in general bode well for accomplishing the applicant's ultimate goal of becoming an independent research clinician.
描述(由申请人提供):帕金森病(PD)是一种常见的神经系统疾病,其症状不断发展为严重残疾和生活质量下降。胶质细胞源性神经营养因子(GDNF)是一种有前途的潜在治疗方法。GDNF是一种天然存在的生长因子,已在多种模型系统中显示其支持在PD中丢失的那些多巴胺能细胞的存活。试图通过产生缺乏这种因子或其受体的小鼠来更多地了解GDNF的功能,但由于伴随的肾脏和胃肠道异常导致出生后早期死亡而受到阻碍。通过使用申请人最近开发的在多巴胺能神经元中表达Cre重组酶的小鼠,并通过使用强大的新化学/遗传技术来产生受体抑制,申请人的总体目标是产生具有GDNF信号传导的细胞类型特异性和时间特异性中断的存活小鼠。这些小鼠将被用作模型系统,以检查内源性GDNF在人PD中丢失的那些细胞的出生后发育和维持中的作用。申请人在约翰霍普金斯的Ted Dawson博士的实验室中所做的初步工作已经产生了实现该目标的初步数据。他对发育生物学和神经退行性疾病的兴趣导致了该项目的制定,并来自NIMH,马里兰州大学和约翰霍普金斯大学的先前研究以及神经病学的临床培训。Dawson实验室(赞助商)在帕金森病模型方面的专业知识,以及与生长因子(Ginty博士)和特异性激酶抑制(Shokat博士)领域的领导者建立的合作,使该项目的成功潜力很高。这与申办者实验室和约翰霍普金斯神经科的丰富环境相结合,总体上预示着申请人将实现成为独立研究临床医生的最终目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH Mark SAVITT其他文献
JOSEPH Mark SAVITT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH Mark SAVITT', 18)}}的其他基金
Development of GDNF Receptor Conditional Knockout Mice
GDNF受体条件性敲除小鼠的研制
- 批准号:
7113793 - 财政年份:2005
- 资助金额:
$ 17.61万 - 项目类别:
Development of GDNF Receptor Conditional Knockout Mice
GDNF受体条件性敲除小鼠的研制
- 批准号:
7236015 - 财政年份:2005
- 资助金额:
$ 17.61万 - 项目类别:
Development of GDNF Receptor Conditional Knockout Mice
GDNF受体条件性敲除小鼠的研制
- 批准号:
6957313 - 财政年份:2005
- 资助金额:
$ 17.61万 - 项目类别:
Development of GDNF Receptor Conditional Knockout Mice
GDNF受体条件性敲除小鼠的研制
- 批准号:
7617699 - 财政年份:2005
- 资助金额:
$ 17.61万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 17.61万 - 项目类别:
Research Grant